Protara Therapeutics is trading at $2.31, down 7.60% in pre-market, with no definitive catalyst established for the October 22 decline. - No fresh company-specific announcement explaining the decline appeared in search results. - The latest identified update was October 15: Protara announced completion of Phase 2b enrollment and remained on track for interim results in Q4 2026. - Major U.S. indices were lower, while biotech’s pre-market move was positive; broader risk-off sentiment may have contributed.